Viewing Study NCT05631795


Ignite Creation Date: 2025-12-24 @ 1:37 PM
Ignite Modification Date: 2025-12-31 @ 3:40 AM
Study NCT ID: NCT05631795
Status: COMPLETED
Last Update Posted: 2025-12-03
First Post: 2022-11-21
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment
Sponsor: Novartis Pharmaceuticals
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Advanced Breast Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None HR+ View
None HER2-negative View
None PI3K View
None CDK4/6 inhibitor View
None ER+ View
None PgR+ View
None men View
None postmenopausal View
None aromatase inhibitor View